Autonomix Medical Announces Issuance of U.S. Patent for Advanced Physiological Signal Capture and Processing Technology

2026-11-10

Investivoq

Autonomix Medical announces U.S. Patent No. 12,793,841, enhancing its proprietary catheter-based physiological signal technology.

Investivoq AI Summary

Autonomix Medical, Inc. has announced the issuance of U.S. Patent No. 12,793,841, which enhances its intellectual property related to advanced physiological signal acquisition and processing technology. This patent covers innovative medical devices and methods that enable high-resolution sensing and real-time monitoring of physiological signals utilizing advanced circuitry. CEO Brad Hauser emphasized that this development reinforces the company’s commitment to precision nerve-targeted interventions, potentially offering physicians deeper insights into neural activity for better treatment decisions. The technology is designed for high-density signal acquisition in catheter-based devices, with possible applications across various medical fields, including cardiovascular interventions and pain management. This patent further solidifies Autonomix's proprietary technology as it progresses in its development and explores additional clinical applications.

Potential Positives

Issuance of a new patent strengthens the company's intellectual property portfolio for its proprietary catheter-based sensing technology.
The patented technology enhances the capability for high-resolution physiological signal acquisition and processing, potentially improving clinical treatment decisions.
Application of the technology may extend across multiple clinical areas, including cardiovascular interventions, electrophysiology, and pain management, signaling versatility in its use.
The CEO's comments highlight the company's commitment to advancing precision nerve-targeted interventions, reinforcing its strategic direction in the medical device field.

Potential Negatives

The technology discussed in the press release is still investigational and has not yet been cleared for marketing in the United States, which raises concerns about the company's ability to monetize its innovations in the near term.
The reliance on forward-looking statements highlighting potential capabilities and applications suggests uncertainty in achieving those expectations, which may affect investor confidence.
Emphasizing the risks and uncertainties associated with the company’s future performance could indicate potential challenges that may hinder its progress and growth.

FAQ

What is the significance of Autonomix's new patent?

The newly issued patent enhances Autonomix's intellectual property, supporting advanced sensing technology for capturing and processing physiological signals.

How does the new patent improve medical device functionality?

The patent covers advanced circuitry that enables high-resolution physiological signal acquisition and real-time monitoring at the biological source.

What clinical applications could benefit from this technology?

This technology may be applied in cardiovascular interventions, electrophysiology, and pain management for precise physiological monitoring.

Is Autonomix's technology available for marketing in the U.S.?

No, the technology is currently investigational and has not yet received marketing clearance in the United States.

How does Autonomix differentiate itself from competitors?

Autonomix's ability to capture and process signals directly at their source differentiates its platform in precision nerve-targeted treatments.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$AMIX Hedge Fund Activity

We have seen 4 institutional investors add shares of $AMIX stock to their portfolio, and 11 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

GEODE CAPITAL MANAGEMENT, LLC added 48,639 shares (+inf%) to their portfolio in Q3 2026, for an estimated $186,287
UBS GROUP AG removed 33,497 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $208,686
LPL FINANCIAL LLC removed 31,435 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $195,840
BANK OF MONTREAL /CAN/ removed 25,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $155,750
VIRTU FINANCIAL LLC removed 12,884 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $80,267
MARINER, LLC removed 2,772 shares (-5.2%) from their portfolio in Q2 2026, for an estimated $17,269
IKARIAN CAPITAL, LLC removed 890 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $5,544

To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

Full Release

Latest patent expands intellectual property protection for advanced physiological signal acquisition and processing

THE WOODLANDS, TX, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the issuance of U.S. Patent No. 12,793,841, titled “ Medical Devices With Circuitry For Capturing And Processing Physiological Signals ,” further strengthening the Company's intellectual property portfolio supporting its proprietary catheter-based sensing technology.

The newly issued patent covers medical devices and methods for capturing and processing physiological signals through advanced sensing and processing circuitry. The technology enables signal acquisition and processing near the biological source, supporting high-resolution sensing, efficient data transmission and real-time physiological monitoring.

“This latest patent further strengthens the intellectual property foundation supporting our proprietary sensing technology and reinforces our commitment to advancing precision nerve-targeted interventions,” commented Brad Hauser, Chief Executive Officer of Autonomix. “Our ability to capture and process physiological signals directly at their source represents what we believe is a key differentiator of our platform. We believe this technology has the potential to provide physicians with greater insight into neural activity and support more precise, informed treatment decisions across a broad range of clinical applications.”

The patented architecture incorporates distributed processing modules, configurable sensing capabilities and efficient data transmission designed to support high-density physiological signal acquisition within catheter-based devices. These capabilities may have applications across cardiovascular interventions, electrophysiology, pain management and other procedures requiring precise physiological monitoring.

The new patent builds upon Autonomix's existing U.S. and international intellectual property portfolio, further strengthening protection for its proprietary sensing technology as the Company advances its development programs and explores additional clinical applications.

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit autonomix.com and connect with the Company on X , LinkedIn , Instagram and Facebook .

Forward Looking Statements

Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release include, but are not limited to, the anticipated significance of the Company’s intellectual property portfolio, the potential capabilities and applications of the Company’s patented sensing technologies, the versatility and scalability of the Company’s platform technology, and the potential for future clinical applications across multiple organ systems.

Although the Company believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 27, 2026, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.

Investor and Media Contact

JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com